XOMA Co. (NASDAQ:XOMA) Director John Varian sold 39,540 shares of XOMA stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $6.24, for a total transaction of $246,729.60. Following the completion of the sale, the director now owns 2,344 shares of the company’s stock, valued at approximately $14,626.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of XOMA Co. (NASDAQ:XOMA) traded up 3.33% during mid-day trading on Thursday, reaching $6.52. 41,242 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $6.70 and a 200 day moving average of $5.69. XOMA Co. has a one year low of $3.96 and a one year high of $14.40. The firm’s market capitalization is $49.19 million.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Thursday, March 16th. The biotechnology company reported ($2.89) EPS for the quarter, missing analysts’ consensus estimates of ($2.32) by $0.57. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.50 million. During the same period last year, the firm earned $0.21 earnings per share. The firm’s revenue for the quarter was down 88.1% compared to the same quarter last year. On average, analysts forecast that XOMA Co. will post ($2.15) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for XOMA (NASDAQ:XOMA)

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/05/18/xoma-co-xoma-director-sells-246729-60-in-stock.html.

XOMA has been the subject of several research analyst reports. Cowen and Company reiterated a “hold” rating on shares of XOMA in a research note on Wednesday, February 1st. Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research note on Thursday, March 23rd. Finally, Wedbush reiterated a “neutral” rating and issued a $9.00 price objective (down previously from $14.00) on shares of XOMA in a research note on Monday, March 27th. Five investment analysts have rated the stock with a hold rating, The company currently has an average rating of “Hold” and a consensus price target of $8.50.

A number of institutional investors have recently bought and sold shares of XOMA. Stonepine Capital Management LLC purchased a new position in XOMA during the first quarter worth about $625,000. Vanguard Group Inc. increased its position in XOMA by 6.4% in the first quarter. Vanguard Group Inc. now owns 206,738 shares of the biotechnology company’s stock worth $1,470,000 after buying an additional 12,474 shares during the period. California Public Employees Retirement System increased its position in XOMA by 95.5% in the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock worth $123,000 after buying an additional 10,640 shares during the period. Finally, WFG Advisors LP purchased a new position in XOMA during the fourth quarter worth about $1,202,000.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

5 Day Chart for NASDAQ:XOMA

Receive News & Ratings for XOMA Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Co. and related companies with MarketBeat.com's FREE daily email newsletter.